Concepts (202)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antineoplastic Combined Chemotherapy Protocols | 20 | 2024 | 2507 | 1.240 |
Why?
|
| Breast Neoplasms | 18 | 2024 | 3022 | 1.200 |
Why?
|
| Pyridines | 8 | 2021 | 300 | 1.160 |
Why?
|
| Kidney Neoplasms | 7 | 2019 | 523 | 0.870 |
Why?
|
| Receptor, ErbB-2 | 7 | 2024 | 247 | 0.790 |
Why?
|
| Antineoplastic Agents | 8 | 2018 | 2331 | 0.750 |
Why?
|
| Carcinoma, Renal Cell | 5 | 2019 | 333 | 0.680 |
Why?
|
| Neoadjuvant Therapy | 8 | 2024 | 376 | 0.630 |
Why?
|
| Triple Negative Breast Neoplasms | 4 | 2024 | 169 | 0.630 |
Why?
|
| Benzenesulfonates | 2 | 2008 | 50 | 0.580 |
Why?
|
| Watchful Waiting | 3 | 2024 | 66 | 0.440 |
Why?
|
| Enzyme Inhibitors | 2 | 2007 | 644 | 0.430 |
Why?
|
| Carcinoma, Small Cell | 2 | 2017 | 133 | 0.410 |
Why?
|
| Chemotherapy, Adjuvant | 6 | 2024 | 476 | 0.400 |
Why?
|
| Comparative Effectiveness Research | 1 | 2012 | 53 | 0.400 |
Why?
|
| Lung Neoplasms | 5 | 2018 | 2370 | 0.400 |
Why?
|
| Urologic Neoplasms | 2 | 2024 | 74 | 0.400 |
Why?
|
| Prostatic Neoplasms | 5 | 2022 | 1747 | 0.390 |
Why?
|
| Capecitabine | 3 | 2021 | 93 | 0.380 |
Why?
|
| Bevacizumab | 8 | 2022 | 268 | 0.360 |
Why?
|
| Neoplasms | 6 | 2023 | 3067 | 0.350 |
Why?
|
| Students, Medical | 3 | 2023 | 425 | 0.350 |
Why?
|
| Middle Aged | 30 | 2024 | 26173 | 0.340 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2016 | 841 | 0.340 |
Why?
|
| Radiosurgery | 3 | 2021 | 287 | 0.340 |
Why?
|
| Medical Oncology | 3 | 2019 | 384 | 0.340 |
Why?
|
| Aged, 80 and over | 17 | 2024 | 6787 | 0.340 |
Why?
|
| Aged | 26 | 2024 | 19272 | 0.330 |
Why?
|
| Receptors, Estrogen | 3 | 2024 | 394 | 0.320 |
Why?
|
| Anilides | 3 | 2019 | 45 | 0.320 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 3 | 2018 | 1131 | 0.310 |
Why?
|
| Neoplasm Staging | 10 | 2024 | 2000 | 0.300 |
Why?
|
| Receptors, Progesterone | 2 | 2019 | 175 | 0.290 |
Why?
|
| Humans | 48 | 2024 | 90014 | 0.290 |
Why?
|
| Prostatectomy | 2 | 2021 | 476 | 0.280 |
Why?
|
| Female | 33 | 2024 | 46617 | 0.280 |
Why?
|
| Bone Neoplasms | 2 | 2019 | 321 | 0.270 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2006 | 67 | 0.270 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2007 | 306 | 0.260 |
Why?
|
| Pyrroles | 2 | 2017 | 172 | 0.250 |
Why?
|
| Disease-Free Survival | 7 | 2024 | 1169 | 0.250 |
Why?
|
| Education, Medical, Undergraduate | 2 | 2019 | 182 | 0.240 |
Why?
|
| Indoles | 2 | 2017 | 301 | 0.240 |
Why?
|
| Neutropenia | 3 | 2021 | 214 | 0.240 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2024 | 1355 | 0.240 |
Why?
|
| Adult | 21 | 2024 | 26836 | 0.240 |
Why?
|
| Nitriles | 3 | 2024 | 156 | 0.230 |
Why?
|
| Trastuzumab | 2 | 2021 | 73 | 0.230 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2021 | 586 | 0.220 |
Why?
|
| Urinary Bladder Neoplasms | 2 | 2024 | 366 | 0.210 |
Why?
|
| Aspirin | 1 | 2024 | 162 | 0.210 |
Why?
|
| Piperazines | 2 | 2021 | 283 | 0.210 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2024 | 151 | 0.210 |
Why?
|
| Androgen Antagonists | 2 | 2021 | 138 | 0.210 |
Why?
|
| Neoplasm Invasiveness | 1 | 2024 | 569 | 0.200 |
Why?
|
| Vegetables | 2 | 2020 | 47 | 0.200 |
Why?
|
| Interdisciplinary Studies | 2 | 2019 | 20 | 0.200 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2024 | 244 | 0.200 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2024 | 204 | 0.200 |
Why?
|
| ErbB Receptors | 1 | 2005 | 499 | 0.200 |
Why?
|
| Schools, Medical | 2 | 2023 | 136 | 0.190 |
Why?
|
| Oxazoles | 1 | 2021 | 18 | 0.190 |
Why?
|
| Antibodies, Monoclonal, Humanized | 3 | 2024 | 952 | 0.190 |
Why?
|
| Clinical Competence | 2 | 2018 | 797 | 0.190 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 1 | 2023 | 105 | 0.190 |
Why?
|
| Double-Blind Method | 5 | 2024 | 1714 | 0.190 |
Why?
|
| Male | 21 | 2024 | 42705 | 0.180 |
Why?
|
| Oncologists | 1 | 2021 | 37 | 0.180 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2021 | 145 | 0.180 |
Why?
|
| Postmenopause | 2 | 2024 | 102 | 0.180 |
Why?
|
| Triazoles | 2 | 2024 | 104 | 0.180 |
Why?
|
| Quinazolines | 1 | 2021 | 212 | 0.170 |
Why?
|
| Leukemia | 1 | 2022 | 322 | 0.170 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2020 | 201 | 0.170 |
Why?
|
| Testosterone | 1 | 2021 | 272 | 0.170 |
Why?
|
| Neoplasm Metastasis | 4 | 2016 | 1066 | 0.160 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2020 | 233 | 0.160 |
Why?
|
| Palliative Medicine | 1 | 2018 | 11 | 0.150 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2019 | 128 | 0.150 |
Why?
|
| Diet | 2 | 2022 | 444 | 0.150 |
Why?
|
| Age Factors | 1 | 2023 | 1880 | 0.150 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2021 | 293 | 0.150 |
Why?
|
| Counseling | 1 | 2020 | 166 | 0.150 |
Why?
|
| Survival Analysis | 4 | 2021 | 1497 | 0.150 |
Why?
|
| Prospective Studies | 5 | 2023 | 4329 | 0.150 |
Why?
|
| Niacinamide | 2 | 2008 | 98 | 0.140 |
Why?
|
| Disease Progression | 5 | 2021 | 1469 | 0.140 |
Why?
|
| Phenylurea Compounds | 2 | 2008 | 95 | 0.140 |
Why?
|
| Biomarkers, Tumor | 2 | 2020 | 1545 | 0.140 |
Why?
|
| Paclitaxel | 4 | 2022 | 474 | 0.140 |
Why?
|
| Cyclooxygenase 2 | 1 | 2017 | 99 | 0.140 |
Why?
|
| Carboplatin | 4 | 2022 | 312 | 0.140 |
Why?
|
| Treatment Outcome | 8 | 2023 | 8292 | 0.140 |
Why?
|
| Curriculum | 2 | 2019 | 573 | 0.140 |
Why?
|
| Survival Rate | 5 | 2019 | 1899 | 0.140 |
Why?
|
| Health Services Misuse | 1 | 2016 | 20 | 0.140 |
Why?
|
| Patient-Centered Care | 1 | 2019 | 210 | 0.130 |
Why?
|
| Prognosis | 5 | 2023 | 3800 | 0.130 |
Why?
|
| Antibodies, Monoclonal | 2 | 2021 | 1396 | 0.130 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2008 | 3481 | 0.130 |
Why?
|
| Follow-Up Studies | 5 | 2024 | 3684 | 0.130 |
Why?
|
| Needs Assessment | 1 | 2016 | 161 | 0.120 |
Why?
|
| Education, Medical, Graduate | 1 | 2018 | 403 | 0.110 |
Why?
|
| Pediatrics | 1 | 2018 | 361 | 0.110 |
Why?
|
| Area Under Curve | 2 | 2018 | 338 | 0.110 |
Why?
|
| Molecular Targeted Therapy | 2 | 2016 | 280 | 0.110 |
Why?
|
| Adenocarcinoma | 1 | 2020 | 1185 | 0.110 |
Why?
|
| Young Adult | 5 | 2024 | 6418 | 0.110 |
Why?
|
| Intensive Care Units | 1 | 2016 | 398 | 0.110 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2024 | 855 | 0.100 |
Why?
|
| Proportional Hazards Models | 2 | 2018 | 848 | 0.100 |
Why?
|
| Quality of Life | 4 | 2022 | 1682 | 0.100 |
Why?
|
| Intention to Treat Analysis | 2 | 2024 | 72 | 0.090 |
Why?
|
| Sirolimus | 1 | 2012 | 162 | 0.090 |
Why?
|
| Hospitalization | 1 | 2016 | 888 | 0.090 |
Why?
|
| Fatigue | 3 | 2017 | 174 | 0.090 |
Why?
|
| Clinical Trials as Topic | 2 | 2021 | 1134 | 0.080 |
Why?
|
| Combined Modality Therapy | 2 | 2023 | 1704 | 0.080 |
Why?
|
| Internship and Residency | 1 | 2018 | 1063 | 0.080 |
Why?
|
| Placebos | 1 | 2008 | 211 | 0.080 |
Why?
|
| Gadolinium DTPA | 1 | 2008 | 256 | 0.070 |
Why?
|
| Oncogenes | 1 | 2007 | 97 | 0.070 |
Why?
|
| Prostate-Specific Antigen | 2 | 2020 | 341 | 0.070 |
Why?
|
| Pandemics | 2 | 2023 | 778 | 0.070 |
Why?
|
| Deoxycytidine | 2 | 2021 | 211 | 0.060 |
Why?
|
| Cell Cycle | 1 | 2007 | 508 | 0.060 |
Why?
|
| Pilot Projects | 2 | 2019 | 872 | 0.060 |
Why?
|
| Thrombocytopenia | 2 | 2017 | 187 | 0.060 |
Why?
|
| United States | 3 | 2024 | 7114 | 0.060 |
Why?
|
| Ki-67 Antigen | 1 | 2024 | 67 | 0.060 |
Why?
|
| Drug Administration Schedule | 2 | 2016 | 865 | 0.060 |
Why?
|
| Cohort Studies | 2 | 2023 | 2887 | 0.060 |
Why?
|
| Canada | 1 | 2024 | 208 | 0.060 |
Why?
|
| Risk Factors | 3 | 2020 | 5562 | 0.060 |
Why?
|
| Abiraterone Acetate | 1 | 2023 | 11 | 0.050 |
Why?
|
| Contrast Media | 1 | 2008 | 1084 | 0.050 |
Why?
|
| Administration, Oral | 1 | 2024 | 667 | 0.050 |
Why?
|
| Cancer Survivors | 1 | 2024 | 95 | 0.050 |
Why?
|
| Prednisone | 1 | 2023 | 255 | 0.050 |
Why?
|
| B7-H1 Antigen | 1 | 2024 | 279 | 0.050 |
Why?
|
| Mastectomy, Segmental | 1 | 2023 | 101 | 0.050 |
Why?
|
| Time Factors | 2 | 2021 | 5361 | 0.050 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2023 | 290 | 0.050 |
Why?
|
| Surveys and Questionnaires | 2 | 2021 | 2658 | 0.050 |
Why?
|
| Ipilimumab | 1 | 2021 | 60 | 0.050 |
Why?
|
| Radiation Oncologists | 1 | 2021 | 14 | 0.050 |
Why?
|
| Breast | 1 | 2023 | 292 | 0.050 |
Why?
|
| Retrospective Studies | 3 | 2023 | 9237 | 0.050 |
Why?
|
| Patient Care Planning | 1 | 2021 | 84 | 0.050 |
Why?
|
| Neoplasm, Residual | 1 | 2022 | 181 | 0.040 |
Why?
|
| Ferredoxin-NADP Reductase | 1 | 2020 | 15 | 0.040 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2020 | 27 | 0.040 |
Why?
|
| Perception | 1 | 2021 | 179 | 0.040 |
Why?
|
| Learning | 1 | 2023 | 286 | 0.040 |
Why?
|
| Telephone | 1 | 2020 | 36 | 0.040 |
Why?
|
| Hypertension | 2 | 2017 | 747 | 0.040 |
Why?
|
| Mastectomy | 1 | 2021 | 246 | 0.040 |
Why?
|
| Evaluation Studies as Topic | 1 | 2019 | 270 | 0.040 |
Why?
|
| Health Personnel | 1 | 2021 | 214 | 0.040 |
Why?
|
| Cisplatin | 1 | 2021 | 598 | 0.040 |
Why?
|
| Neovascularization, Pathologic | 1 | 2021 | 354 | 0.040 |
Why?
|
| Training Support | 1 | 2018 | 23 | 0.040 |
Why?
|
| Tamoxifen | 1 | 2019 | 168 | 0.040 |
Why?
|
| Prostate | 1 | 2022 | 407 | 0.040 |
Why?
|
| Consolidation Chemotherapy | 1 | 2018 | 23 | 0.040 |
Why?
|
| Hemoptysis | 1 | 2018 | 24 | 0.040 |
Why?
|
| Interprofessional Relations | 1 | 2019 | 121 | 0.040 |
Why?
|
| Radiation Pneumonitis | 1 | 2018 | 21 | 0.040 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2017 | 33 | 0.040 |
Why?
|
| Celecoxib | 1 | 2017 | 31 | 0.040 |
Why?
|
| Germ-Line Mutation | 1 | 2020 | 347 | 0.040 |
Why?
|
| Dinoprostone | 1 | 2017 | 70 | 0.040 |
Why?
|
| Pemetrexed | 1 | 2017 | 76 | 0.040 |
Why?
|
| Platinum Compounds | 1 | 2017 | 30 | 0.040 |
Why?
|
| Maximum Tolerated Dose | 1 | 2018 | 263 | 0.040 |
Why?
|
| Mucositis | 1 | 2017 | 17 | 0.040 |
Why?
|
| Educational Measurement | 1 | 2019 | 231 | 0.030 |
Why?
|
| Drug Eruptions | 1 | 2017 | 33 | 0.030 |
Why?
|
| Program Evaluation | 1 | 2018 | 312 | 0.030 |
Why?
|
| Signal Transduction | 1 | 2007 | 3404 | 0.030 |
Why?
|
| Maintenance Chemotherapy | 1 | 2017 | 84 | 0.030 |
Why?
|
| Selection Bias | 1 | 2016 | 36 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2018 | 682 | 0.030 |
Why?
|
| Anemia | 1 | 2017 | 132 | 0.030 |
Why?
|
| Standard of Care | 1 | 2016 | 65 | 0.030 |
Why?
|
| Transcriptome | 1 | 2020 | 661 | 0.030 |
Why?
|
| Genotype | 1 | 2020 | 1852 | 0.030 |
Why?
|
| Terminal Care | 1 | 2016 | 137 | 0.030 |
Why?
|
| Biomarkers | 1 | 2021 | 1778 | 0.030 |
Why?
|
| Incidence | 1 | 2018 | 1604 | 0.030 |
Why?
|
| Cyclophosphamide | 1 | 2014 | 301 | 0.030 |
Why?
|
| Doxorubicin | 1 | 2014 | 293 | 0.030 |
Why?
|
| Biopsy | 1 | 2017 | 1184 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2020 | 2327 | 0.030 |
Why?
|
| Remission Induction | 1 | 2014 | 741 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2020 | 2415 | 0.020 |
Why?
|
| MicroRNAs | 1 | 2016 | 556 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2014 | 1929 | 0.020 |
Why?
|
| Fluorouracil | 1 | 2011 | 549 | 0.020 |
Why?
|
| Child | 1 | 2018 | 7242 | 0.020 |
Why?
|
| Chicago | 1 | 2011 | 1434 | 0.020 |
Why?
|
| Mutation | 1 | 2012 | 4169 | 0.010 |
Why?
|